ArticleFrontiers in nutrition2025
The associations of maternal serum ferritin levels with hypertensive disorders of pregnancy: a longitudinal cohort study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Maternal Overnutrition and Fetal Programming: Long-Term Metabolic, Cognitive, and Epigenetic Consequences.Cells · 2026Review
- First-trimester ferritin levels and gestational diabetes mellitus risk in twin pregnancies: a retrospective cohort study.BMC pregnancy and childbirth · 2026Article
- Early-pregnancy serum iron as a nutrition-related clinical laboratory indicator for preeclampsia risk stratification: a retrospective cohort study.Frontiers in nutrition · 2026Article
- Maternal serum ferritin across gestation and risk of small-for-gestational-age: a longitudinal cohort study.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The longitudinal fluctuations in maternal serum ferritin (SF) levels during gestation, acting as indirect indicators of iron supplementation, have not been thoroughly investigated in relation to the incidence of hypertensive disorders of pregnancy (HDP). Methods: A retrospective cohort investigation was carried out at a tertiary maternity hospital in Shanghai, involving women with serum ferritin (SF) measurements at 8.0-13.6 gestational weeks (GW) and at 29.0-31.6 GW. Logistic regression analysis was employed to evaluate the relationship between maternal SF levels, their longitudinal variations, with the risk of HDP. Results: The study included 17,472 women, among whom 473(2.71%) developed gestational hypertension (GH) and 560(3.21%) developed preeclampsia (PE). Adjusted odds ratios (ORs; 95% confidence intervals) for HDP across ascending quartiles of SF concentrations were as follows: at 8.0-13.6 GW, 1.00 (reference), 1.043 (0.864-1.258), 1.060 (0.878-1.279), and 1.234 (1.027-1.482); and at 29.0-31.6 GW, 1.00 (reference), 0.973 (0.800-1.181), 1.076 (0.890-1.301), and 1.299 (1.082-1.560). Women with SF levels in the highest quartile at 8.0-13.6 GW exhibited reduced HDP risk when their SF levels declined to the lowest quartile by 29.0-31.6 GW. Conversely, those with SF levels in the lowest quartile early in pregnancy but transitioning to the highest quartile later in pregnancy demonstrated a significantly elevated HDP incidence (8.2%; OR: 1.445, 95% CI: 1.003-2.081). Conclusion: Maternal SF levels demonstrated an independent positive association with HDP risk during early and late gestational stages. These findings suggest that routine iron supplementation in iron-replete women may exacerbate HDP risk and warrants careful reconsideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.